Robert Coleman, Frcp

List of Publications by Year
in descending order

48 papers	2,656 citations	257450 24 h-index	189892 50 g-index

52 all docs	52 docs citations	52 times ranked	3693 citing authors

#	Article	IF	Citations
1	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncology, The, 2014, 15, 738-746.	10.7	433
2	Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG) Tj ETQq0 0 0 rgBT /Overlock 10 T	10.7	247
3	Effects of Bone-Targeted Agents on Cancer Progression and Mortality. Journal of the National Cancer Institute, 2012, 104, 1059-1067.	6.3	171
4	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 60-72.	10.7	161
5	Metastatic bone disease: Pathogenesis and therapeutic options. Journal of Bone Oncology, 2019, 15, 100205.	2.4	153
6	Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncology, The, 2014, 15, 114-122.	10.7	109
7	Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treatment Reviews, 2008, 34, 629-639.	7.7	108
8	A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Research and Treatment, 2014, 145, 411-418.	2.5	95
9	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. Journal of the National Cancer Institute, 2015, 107, djv256.	6.3	90
10	Bone health during endocrine therapy for cancer. Lancet Diabetes and Endocrinology,the, 2018, 6, 901-910.	11.4	85
11	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	4.4	84
12	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. European Urology, 2015, 68, 850-858.	1.9	74
13	The role of biomarkers in the management of bone-homing malignancies. Journal of Bone Oncology, 2017, 9, 1-9.	2.4	71
14	The use of bisphosphonates in cancer treatment. Annals of the New York Academy of Sciences, 2011, 1218, 3-14.	3.8	66
15	Cancer Treatment and Bone Health. Calcified Tissue International, 2018, 102, 251-264.	3.1	60
16	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, The, 2017, 18, 929-945.	10.7	58
17	Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223. Seminars in Nuclear Medicine, 2016, 46, 99-104.	4.6	47
18	Zoledronic acid use in cancer patients. Cancer, 2011, 117, 11-23.	4.1	46

#	Article	IF	Citations
19	Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncology, The, 2017, 18, 1543-1552.	10.7	45
20	The value of biomarkers in bone metastasis. European Journal of Cancer Care, 2017, 26, e12725.	1.5	39
21	Zoledronic acid. Expert Opinion on Drug Safety, 2011, 10, 133-145.	2.4	36
22	The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Research and Treatment, 2016, 155, 151-157.	2.5	32
23	Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial. Journal of the National Cancer Institute, 2018, 110, 871-879.	6.3	32
24	Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. European Journal of Cancer, 2018, 94, 70-78.	2.8	31
25	Potential Use of Bisphosphonates in the Prevention of Metastases in Early-Stage Breast Cancer. Clinical Breast Cancer, 2007, 7, S29-S35.	2.4	23
26	New results from the use of bisphosphonates in cancer patients. Current Opinion in Supportive and Palliative Care, 2009, 3, 213-218.	1.3	22
27	Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology, 2017, 35, 2507-2514.	1.6	22
28	Denosumab and fracture risk in women with breast cancer. Lancet, The, 2015, 386, 409-410.	13.7	21
29	Experience with denosumab (XGEVAÂ®) for prevention of skeletal-related events in the 10 years after approval. Journal of Bone Oncology, 2022, 33, 100416.	2.4	21
30	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 755-769.	10.7	18
31	Managing metastatic bone disease: Three case studies. Seminars in Oncology, 2004, 31, 83-86.	2.2	17
32	Bisphosphonates and breast cancer â€“ From cautious palliation to saving lives. Bone, 2020, 140, 115570.	2.9	14
33	Bone targeted treatments in cancer â€“ The story so far. Journal of Bone Oncology, 2016, 5, 90-92.	2.4	12
34	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment, 2018, 169, 1-7.	2.5	12
35	Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 29-38.	3.3	12
36	Clinical benefits of bone targeted agents in early breast cancer. Breast, 2019, 48, S92-S96.	2.2	12

#	Article	IF	Citations
37	Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer, 2022, 126, 419-429.	6.4	10
38	New Roles for Bisphosphonates in Cancer Therapy. Progress in Palliative Care, 1996, 4, 39-43.	1.2	7
39	Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer. JAMA Oncology, 2016, 2, 423.	7.1	6
40	Natural history of stage II/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences. Journal of Bone Oncology, 2021, 28, 100367.	2.4	4
41	Commentary: Controversies in NICE guidance on metastatic spinal cord compression. BMJ: British Medical Journal, 2008, 337, a2555-a2555.	2.3	4
42	Code of practice needed for samples donated by trial participants. Lancet Oncology, The, 2022, 23, e89-e90.	10.7	4
43	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. British Journal of Cancer, 2021, 124, 1373-1378.	6.4	3
44	Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. Journal of Bone and Mineral Research, 2020, 36, 1906-1913.	2.8	3
45	Adjuvant denosumab in early breast cancer â€“ Authors' reply. Lancet Oncology, The, 2020, 21, e125.	10.7	2
46	Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma.. Blood, 2007, 110, 1499-1499.	1.4	1
47	Predictors for Skeletal-Related Events in Patients with Advanced Multiple Myeloma.. Blood, 2007, 110, 1482-1482.	1.4	1
48	Bone Oncologyâ€”An emerging multi-disciplinary specialty. Journal of Bone Oncology, 2012, 1, 1.	2.4	0